Oct 27 (Reuters) – Cipla, India's third-largest drugmaker by revenue, missed second-quarter profit estimates on Tuesday, as muted sales of generic Revlimid and stiff competition weighed on its US
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Oct 27 (Reuters) - Russian President Vladimir Putin may speak with Finland's President Alexander Stubb…
By Olesya Astakhova and Ahmad Ghaddar MOSCOW/LONDON, Oct 27 - OPEC+ oil-producing countries are likely…
By Eduardo Baptista and Laurie Chen Oct 26 (Reuters) - A US federal judge on…
IRAN'S PERSIAN GULF STRAIT AUTHORITY SAYS ALL VESSELS BELONGING TO SINOKOR SHIPPING COMPANY WILL BE…
Introduces energy-efficient Inverter and Fixed-Speed Split ACs featuring Eco Inverter technology, 7-in-1 Flexi Cooling, 100%…
Oct 27 (Reuters) - Sealmatic India Ltd: * SEALMATIC INDIA - APPROVES FUND RAISING OF…